News

Lighthouse Labs Announces Newest Cohort

The three Richmond businesses will join six others — including two from elsewhere in Virginia — as part of the 12th cohort of businesses to go through Lighthouse Labs, a program that provides mentoring, advice and financial support to promising startup businesses.

This year marks the 10th year that Lighthouse Labs has operated. Including this spring’s cohort, Lighthouse Labs has worked with 89 companies and more than 160 founders.

“Over the course of the last decade, we’ve attracted some of the most talented founders and mentors to the Richmond startup community,” said Erin Powell, executive director of Lighthouse Labs. “The support for growing our startup ecosystem here in Richmond has been growing steadily for the last few years.”

The spring 2022 cohort will meet for regularly for 12 weeks starting March 7, and will get mentoring from numerous volunteers and advisory services from Lighthouse Labs’ partners such as Global Accelerator Network, Kaleo Legal, Sandbox and Startup Virginia.

Lighthouse received more than 160 applications for the nine spots in the upcoming cohort.

Five of the nine companies are in Virginia. Two are based in Pennsylvania and two based in Texas.

Six of the nine teams are in the healthcare industry. “There is a lot of focus on healthcare,” said Powell, adding that Lighthouse Labs continues to partner with a consortium of health providers including Virginia Commonwealth University to help bring health innovations to market.

Companies participating in the program also get $20,000 of equity-free funding.

The companies in the spring 2022 cohort are:

Llamawood,

  • a Richmond-based on-demand firewood delivery platform;

LipLoveLine,

  • a Richmond-based ingredient-conscious lip care brand;

Nessle,

  • a Richmond-based online platform that connects new and expectant parents to perinatal experts for on-demand care;

Transfoam,

  • A Charlottesville-based biotechnology firm using engineered microorganisms to turn waste into biodegradable plastic alternatives

Kinometrix,

  • a Fort Belvoir-based developer of an artificial intelligence platform to enhance patient safety in hospitals;

On Time Trials,

  • a Round Rock, Texas, software company using machine learning to optimize clinical trial monitoring;

Hoth Intelligence,

  • a Philadelphia company that provides augmented reality solutions for medical problems;

Viora,

  • a Philadelphia company that reduces health risks due to social and behavioral determinants, and

CaseCTRL,

  • a Houston-based software developer of surgical case management systems.

Learn more here.

Recent News

07/20/2026

U.S. Department of Commerce Intends to Invest $169 Million in Tech Hubs Funding to Enhance Economic Competitiveness and National Security

Today, the U.S. Department of Commerce announced that the Economic Development Administration (EDA) intends to award $169 million across six selected Tech Hubs to advance U.S. leadership in industries essential to our economic competitiveness and national security. These projects are part of EDA’s Regional Technology and Innovation Hubs (Tech Hubs) program, which serves as a key investment in this Administration’s America First agenda, investing in regions

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE